Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.55 |
| ▸ | FPR2 | P25090 | 5/20 | 0.43 |
| ▸ | FPR3 | P25089 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23291509 | 1.00 | RORC (0.55) | RORCFPR2FPR3GPR119STS | |
| SCHEMBL16611368 | 0.89 | RORC (0.43) | RORCGPR119STSPTPN2PTPN1 | |
| SCHEMBL35211565 | 0.88 | STS (0.52) | RORCGPR119STS | |
| SCHEMBL23538696 | 0.88 | ALDH1A1 (0.44) | RORCGPR119STSPTPN2PTPN1 | |
| SCHEMBL16874573 | 0.87 | ALDH1A1 (0.55) | GPR119STS | |
| SCHEMBL16874571 | 0.87 | ALDH1A1 (0.55) | GPR119STS | |
| SCHEMBL31702241 | 0.86 | PTPN2 (0.47) | RORCGPR119STSPTPN2PTPN1 | |
| SCHEMBL22551229 | 0.85 | KMT2A (0.43) | RORCGPR119STSPTPN2PTPN1 | |
| SCHEMBL23538342 | 0.84 | ALDH1A1 (0.54) | RORCGPR119STS | |
| SCHEMBL31700556 | 0.84 | GPR119 (0.52) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | RORC 231/4885FPR2 3200/4885FPR3 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.